Medigene AG
Records under this name other than the patents Medigene AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,413,511 | Liposomal formulations of lipophilic compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,858,662 | Medicament for the treatment of viral skin and tumour diseases Formerly held Term ended Term ended Oct 2, 2026 · From the USPTO record | Term ended | Term ended Oct 2, 2026 | From the USPTO record |
| US 9,827,196 | Method of administering a cationic liposomal preparation Lapsed on the fee record Ended Nov 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 28, 2025 | From the USPTO record |
| US 7,932,253 | Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors Term ended Term ended Aug 23, 2025 · From the USPTO record | Term ended | Term ended Aug 23, 2025 | From the USPTO record |
| US 9,707,204 | Treatment of breast cancer Formerly held Lapsed on the fee record Ended Jul 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 18, 2025 | From the USPTO record |
| US 9,770,406 | Medicament for the treatment of viral skin and tumour diseases Formerly held Term ended Term ended Jul 12, 2025 · From the USPTO record | Term ended | Term ended Jul 12, 2025 | From the USPTO record |
| US 7,566,713 | Immuno inhibitory heterocyclic compounds Term ended Term ended Apr 26, 2025 · From the USPTO record | Term ended | Term ended Apr 26, 2025 | From the USPTO record |
| US 8,455,022 | Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin Formerly held Term ended Term ended Oct 8, 2024 · From the USPTO record | Term ended | Term ended Oct 8, 2024 | From the USPTO record |
| US 8,309,552 | Immunomodulating heterocyclic compounds Term ended Term ended Oct 2, 2024 · From the USPTO record | Term ended | Term ended Oct 2, 2024 | From the USPTO record |
| US 8,168,216 | Treatment of triple receptor negative breast cancer Formerly held Lapsed on the fee record Ended May 1, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2024 | From the USPTO record |